Completed

Viracept Safety and Efficacy in AIDS Patients with CMV Retinitis

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Nelfinavir mesylate

Drug
Who is being recruted

Blood-Borne Infections+22

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
See protocol details

Summary

Principal SponsorAgouron Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on AIDS patients who are currently undergoing treatment for a specific eye infection called cytomegalovirus (CMV) retinitis. The main goal is to evaluate if a drug named Viracept can safely and effectively improve the treatment outcome for these patients. The importance of this study lies in its potential to enhance the care and management of CMV retinitis in AIDS patients, addressing the current challenges associated with this condition.

NCT00002169
Principal SponsorAgouron Pharmaceuticals
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesCytomegalovirus InfectionsDNA Virus InfectionsEye DiseasesHerpesviridae InfectionsImmunologic Deficiency SyndromesImmune System DiseasesInfectionsOpportunistic InfectionsRetinal DiseasesRetinitisRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesVirus DiseasesSexually Transmitted Diseases, ViralEye InfectionsEye Infections, ViralLentivirus InfectionsHIV InfectionsAIDS-Related Opportunistic InfectionsCytomegalovirus Retinitis

Criteria

2 inclusion criteria required to participate
HIV infection
Newly diagnosed or first progression of CMV retinitis
1 exclusion criteria prevent from participating
Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 8 locations

Univ of Southern California / LA County USC Med Cntr

Los Angeles, United StatesOpen Univ of Southern California / LA County USC Med Cntr in Google Maps

Univ of California / UCI Med Ctr

Orange, United States

Univ of California / San Diego Treatment Ctr

San Diego, United States

Harbor UCLA Med Ctr

Torrance, United States
Completed8 Study Centers